Table 2. Active clinical drugs for the prevention and treatment of bladder cancer.
Drugs | Identifier | Targets | Role | References |
---|---|---|---|---|
Meloxicam | NSAID | Unknown | Inhibition | 146 |
Celecoxib | COX-2 inhibitor | COX-2 | Inhibition | 148 |
BCG | Vaccine | Cytokines/chemokines and T cells | Inhibition | 151-155 |
IL-15 | Gene therapy | T lymphocytes | Inhibition | 161 |
IL-10 blocking antibodies | antibody | Th1 | Inhibition | 162 |
Ipilimumab | CTLA-4 inhibitor | CTLA-4 | Investigation | 164 |
Atezolizumab | PD-L1 inhibitor | PD-L1 | Inhibition | 167 |
Nivolumab | PD-1 inhibitor | PD-1 | Inhibition | 167 |
Pembrolizumab | PD-1 inhibitor | PD-1 | Inhibition | 164, 168 |